CN Patent

CN112336723B — 制备用于降低trpv4与nox2耦联度的药物的方法

Assigned to Jiangnan University · Expires 2023-09-26 · 3y expired

What this patent protects

本发明公开了制备用于降低TRPV4与NOX2耦联度的药物的方法，属于化学医药技术领域。本发明将恩曲替尼、L755507、藤黄酸、M12化合物作为活性成分，应用在制备用于降低TRPV4与NOX2耦联度、抗氧化应激和血管通透性的药物中，实现对肥胖患者中TRPV4与NOX2过度偶联情况的耦联度降低，使得过度偶联的两个蛋白解耦联，使其恢复正常状态，使得使肥胖患者氧化应激及血管通透性恢复正常水平。

USPTO Abstract

本发明公开了制备用于降低TRPV4与NOX2耦联度的药物的方法，属于化学医药技术领域。本发明将恩曲替尼、L755507、藤黄酸、M12化合物作为活性成分，应用在制备用于降低TRPV4与NOX2耦联度、抗氧化应激和血管通透性的药物中，实现对肥胖患者中TRPV4与NOX2过度偶联情况的耦联度降低，使得过度偶联的两个蛋白解耦联，使其恢复正常状态，使得使肥胖患者氧化应激及血管通透性恢复正常水平。

Drugs covered by this patent

Patent Metadata

Patent number
CN112336723B
Jurisdiction
CN
Classification
—
Expires
2023-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Jiangnan University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.